Synergistic, multi-level understanding of psychedelics: three systematic reviews and meta-analyses of their pharmacology, neuroimaging and phenomenology
This systematic review (2024) and meta-analysis (s=44) finds that medium/high doses of LSD yield higher ratings of visionary restructuralisation than psilocybin. It also reports that psychedelics strengthen between-network functional connectivity and diminish within-network connectivity, and that LSD induces more inositol phosphate formation at the 5-HT2A receptor than DMT or psilocin, while receptor selectivity differences remain negligible.
Authors
- Robin Carhart-Harris
- Katrin Preller
- Morten Kringelbach
Published
Abstract
Serotonergic psychedelics induce altered states of consciousness and have shown potential for treating a variety of neuropsychiatric disorders, including depression and addiction. Yet their modes of action are not fully understood. Here, we provide a novel, synergistic understanding of psychedelics arising from systematic reviews and meta-analyses of three hierarchical levels of analysis: (1) subjective experience (phenomenology), (2) neuroimaging and (3) molecular pharmacology. Phenomenologically, medium and high doses of LSD yield significantly higher ratings of visionary restructuralisation than psilocybin on the 5-dimensional Altered States of Consciousness Scale. Our neuroimaging results reveal that, in general, psychedelics significantly strengthen between-network functional connectivity (FC) while significantly diminishing within-network FC. Pharmacologically, LSD induces significantly more inositol phosphate formation at the 5-HT2A receptor than DMT and psilocin, yet there are no significant between-drug differences in the selectivity of psychedelics for the 5-HT2A, 5-HT2C, or D2 receptors, relative to the 5-HT1A receptor. Our meta-analyses link DMT, LSD, and psilocybin to specific neural fingerprints at each level of analysis. The results show a highly non-linear relationship between these fingerprints. Overall, our analysis highlighted the high heterogeneity and risk of bias in the literature. This suggests an urgent need for standardising experimental procedures and analysis techniques, as well as for more research on the emergence between different levels of psychedelic effects.
Research Summary of 'Synergistic, multi-level understanding of psychedelics: three systematic reviews and meta-analyses of their pharmacology, neuroimaging and phenomenology'
Introduction
Serotonergic psychedelics — including DMT, LSD, and psilocybin — alter consciousness profoundly and have attracted renewed clinical interest for neuropsychiatric disorders, yet their mechanisms remain incompletely understood. Prior research has typically examined each level of analysis — subjective phenomenology, functional neuroimaging, and molecular pharmacology — in isolation, precluding meaningful cross-level synthesis. This paper aimed to resolve that limitation by conducting systematic reviews and meta-analyses at all three hierarchical levels simultaneously for the three classical tryptamine psychedelics, and integrating the findings using a common framework based on the seven canonical Yeo resting-state cortical networks.
Expert Research Summaries
Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.
Full Text PDF
Full Paper PDF
Pro members can view the original manuscript directly in the browser.
Study Details
- Study Typemeta
- Journal
- Compounds
- Topics
- Authors
- APA Citation
Shinozuka, K., Jerotic, K., Mediano, P., Zhao, A. T., Preller, K. H., Carhart-Harris, R., & Kringelbach, M. L. (2024). Synergistic, multi-level understanding of psychedelics: three systematic reviews and meta-analyses of their pharmacology, neuroimaging and phenomenology. Translational Psychiatry, 14(1). https://doi.org/10.1038/s41398-024-03187-1
References (65)
Papers cited by this study that are also in Blossom
Nutt, D. J., Erritzoe, D., Carhart-Harris, R. L. · Cell (2020)
Tófoli, L. F., De Araujo, D. B. · International Review of Neurobiology (2016)
Goodwin, G. M., Malievskaia, E., Fonzo, G. A. et al. · American Journal of Psychiatry (2023)
Griffiths, R. R., Johnson, M. W., Richards, W. A. et al. · Journal of Psychopharmacology (2017)
Yaden, D. B., Johnson, M. W., Griffiths, R. R. et al. · International Journal of Neuropsychopharmacology (2021)
Studerus, E., Gamma, A., Vollenweider, F. X. · PLOS ONE (2010)
Holze, F., Ley, L., Müller, F. et al. · Neuropsychopharmacology (2022)
Ley, L., Holze, F., Arikci, D. et al. · Neuropsychopharmacology (2023)
Qiu, X., Minda, J. P. · Psyarxiv (2021)
Sanz, C., Zamberlan, F., Erowid, E. et al. · Frontiers in Neuroscience (2018)
Show all 65 referencesShow fewer
Zamberlan, F., Sanz, C., Pallavicini, C. et al. · Frontiers in Integrative Neuroscience (2018)
Carhart-Harris, R. L., Erritzoe, D., Williams, T. et al. · PNAS (2012)
Carhart-Harris, R. L., Roseman, L., Bolstridge, M. et al. · Scientific Reports (2017)
Daws, R. E., Timmermann, C., Giribaldi, B. et al. · Nature Medicine (2022)
Doss, M. K., Považan, M., Rosenberg, M. D. et al. · Translational Psychiatry (2021)
Mertens, L. J., Wall, M. B., Roseman, L. et al. · Journal of Psychopharmacology (2020)
Roseman, L., Demetriou, L., Wall, M. B. et al. · Neuropharmacology (2018)
Carhart-Harris, R. L., Leech, R., Shanahan, M. et al. · Frontiers in Human Neuroscience (2014)
Carhart-Harris, R. L. · Neuropharmacology (2018)
Gonza ´lez-Maeso, J., Weisstaub, N. V., Zhou, M. et al. · Neuron (2007)
López-Giménez, J. F., González-Maeso, J. · Current Topics in Behavioral Neurosciences (2017)
Preller, K. H., Herdener, M., Pokorny, T. et al. · Current Biology (2017)
Quednow, B. B., Kometer, M., Geyer, M. A. et al. · Neuropsychopharmacology (2011)
Vollenweider, F. X., Vollenweider-Scherpenhuyzen, M. F. I., Bäbler, A. et al. · NeuroReport (1998)
Canal, C. E., Murnane, K. S. · Journal of Psychopharmacology (2016)
Pokorny, T., Preller, K. H., Kraehenmann, R. et al. · European Neuropsychopharmacology (2016)
Luan, L. X., Eckernäs, E., Ashton, M. et al. · Journal of Psychopharmacology (2023)
Vogt, S. B., Ley, L., Erne, L. et al. · Translational Psychiatry (2023)
Carbonaro, T. M., Hurwitz, E., Johnson, M. W. · Psychopharmacology (2017)
Vollenweider, F. X., Csomor, P. A., Knappe, B. et al. · Neuropsychopharmacology (2007)
Carhart-Harris, R. L., Muthukumaraswamy, S., Roseman, L. et al. · PNAS (2016)
Bedford, P., Hauke, D. J., Wang, Z. et al. · Neuropsychopharmacology (2022)
Barrett, F. S., Krimmel, S. R., Griffiths, R. R. et al. · NeuroImage (2020)
Rickli, A., Moning, O. D., Hoener, M. C. et al. · European Neuropsychopharmacology (2016)
Kringelbach, M. L., Cruzat, J., Cabral, J. et al. · PNAS (2020)
Burt, J. B., Preller, K. H., Demirtaş, M. et al. · eLife (2021)
Barrett, F. S., Doss, M. K., Sepeda, N. D. et al. · Scientific Reports (2020)
Girn, M., Roseman, L., Bernhardt, B. et al. · NeuroImage (2022)
Lebedev, A. V., L€ Ovd En, M., Rosenthal, G. et al. · Human Brain Mapping (2015)
Madsen, M. K., Stenbaek, D. S., Arvidsson, A. et al. · European Neuropsychopharmacology (2021)
Müller, F., Dolder, P. C., Schmidt, A. et al. · NeuroImage (2018)
Roseman, L., Leech, R., Feilding, A. et al. · Frontiers in Human Neuroscience (2014)
Duerler, P., Brem, S., Fraga-González, G. et al. · Cerebral Cortex (2021)
Timmermann, C., Spriggs, M. J., Kaelen, M. et al. · Neuropharmacology (2018)
Kometer, M., Vollenweider, F. X. · Behavioral Neurobiology of Psychedelic Drugs (2016)
Goodwin, G. M., Aaronson, S. T., Alvarez, O. et al. · New England Journal of Medicine (2022)
Raison, C. L., Sanacora, G., Woolley, J. D. et al. · JAMA (2023)
Schindowski, E. M., Jungwirth, J., Schuldt, A. et al. · EClinicalMedicine (2023)
Tagliazucchi, E., Roseman, L., Kaelen, M. et al. · Current Biology (2016)
Moreton, S. G., Szalla, L., Menzies, R. E. et al. · Psychopharmacology (2019)
Nour, M. R., Evans, J., Nutt, D. J. et al. · Frontiers in Human Neuroscience (2016)
Atasoy, S., Leor, R., Kaelen, M. et al. · Scientific Reports (2017)
Luppi, A. I., Carhart-Harris, R. L., Roseman, L. et al. · NeuroImage (2021)
Palhano-Fontes, F., Andrade, K. C., Tófoli, L.F. et al. · PLOS ONE (2015)
Pasquini, L., Palhano-Fontes, F., Araújo, D. B. · Journal of Psychopharmacology (2020)
Smigielski, L., Scheidegger, M., Kometer, M. et al. · NeuroImage (2019)
Carhart-Harris, R. L., Leech, R., Erritzoe, D. et al. · Schizophrenia Bulletin (2012)
Doss, M. K., May, D. G., Johnson, M. W. et al. · Scientific Reports (2020)
Linguiti, S., Vogel, J. W., Sydnor, V. J. et al. · Neuroscience and Biobehavioral Reviews (2023)
Kaelen, M., Roseman, L., Kahan, J. et al. · European Neuropsychopharmacology (2016)
Grimm, O., Kraehenmann, R., Preller, K. H. et al. · European Neuropsychopharmacology (2018)
Lawn, T., Dipasquale, O., Vamvakas, A. et al. · Psychopharmacology (2022)
Deco, G., Cruzat, J., Cabral, J. et al. · Current Biology (2018)
Cruzat, J., Perl, Y. S., Escrichs, A. et al. · Network Neuroscience (2022)
Roseman, L., Nutt, D. J., Carhart-Harris, R. L. · Frontiers in Pharmacology (2018)
Cited By (2)
Papers in Blossom that reference this study
Jacobs, E., Zahid, Z., Hinkle, J. et al. · BMJ (2026)
Singleton, S. P., Timmermann, C., Luppi, A. I. et al. · Communications Biology (2025)
Your Personal Research Library
Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.